RT Journal Article
SR Electronic
T1 Single-cell characterization of peripheral blood mononuclear cells from vedolizumab-treated patients with Crohn’s disease identifies response-associated differences among the plasmacytoid dendritic cell and classical monocyte populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.23.23291732
DO 10.1101/2023.06.23.23291732
A1 Li Yim, Andrew Y.F.
A1 Hageman, Ishtu L.
A1 Joustra, Vincent
A1 Elfiky, Ahmed
A1 Ghiboub, Mohammed
A1 Levin, Evgeni
A1 Verhoeff, Jan
A1 Verseijden, Caroline
A1 Admiraal-van den Berg, Iris
A1 Mannens, Marcel M.A.M.
A1 Jakobs, Marja E.
A1 Kenter, Susan B.
A1 Adams, Alex T.
A1 Satsangi, Jack
A1 D’Haens, Geert R.
A1 de Jonge, Wouter J.
A1 Henneman, Peter
YR 2024
UL http://medrxiv.org/content/early/2024/05/23/2023.06.23.23291732.abstract
AB Vedolizumab (VDZ) is a monoclonal antibody approved for the treatment of Crohn’s disease (CD). Despite its efficacy, non-response to VDZ is common in clinical practice with no clear understanding of how it manifests. Here, we characterized the cellular repertoire of responders and non-responders to VDZ during treatment. Peripheral blood mononuclear cells (PBMCs) were isolated from CD patients on VDZ treatment that were either steroid-free responder (N = 4) or non-responder (N = 4). Response was defined as ≥3 drop in Simple Endoscopic Score for Crohn’s Disease (SES-CD) in combination with a ≥50% reduction in C-reactive protein (CRP) and fecal calprotectin and/or a ≥3 point drop in Harvey-Bradshaw Index (HBI). Single-cell repertoires were characterized using single-cell RNA-sequencing (scRNAseq) and mass cytometry by time of flight (CyTOF). Non-responders to VDZ presented more T cells, but fewer myeloid cells. T cells from non-responders presented lower expression of NFкB signaling inhibitors. A lower relative abundance of plasmacytoid dendritic cells (pDCs) was observed among non-responders. Moreover, non-responder-derived classical monocytes presented lower expression of genes involved in wound-healing and cytokine-cytokine receptor signaling. Taken together, non-response to VDZ during treatment is associated with differences in abundance and expression among T and myeloid cells.Competing Interest StatementThe following authors disclose the following within the past 5 years. ALY received honoraria from Janssen, Johnson & Johnson, DeciBio and was employed by GSK. WJ received speaker fees from Janssen, Johnson & Johnson. GRD received speaker fees from Janssen, Johnson & Johnson. The remaining authors disclose no conflicts.Funding StatementThis study was funded by the Helmsley Foundation as well as local funds from the Department of Human Genetics and the Tytgat Institute for Liver and Intestinal Research, AmsterdamUMC University of Amsterdam, Amsterdam, NetherlandsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medisch Ethische Toetsingscommissie (METC) of the Amsterdam Universitair Medische Centra, location Academisch Medisch Centrum, gave ethical approval for this work under reference number: NL53989.018.15.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw data produced are available online at the European Genome-phenome Archive. The single-cell RNA-sequencing data can be found under accession number EGAS00001007328. The bulk RNA-sequencing data on classical monocytes can be found under accession number EGAS00001007361. All scripts can be found at https://github.com/ND91/HGPRJ0000008_EPICCD_anti_a4b7_sc